CompletedPhase 2NCT00581360
Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck
Studying Adenoid cystic carcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Pittsburgh
- Principal Investigator
- Athanassios E Argiris, MD, MDPrincipal Investigator
- Intervention
- doxorubicin and bortezomib(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2011
Study locations (21)
- UPMC Cancer Center - Teramana Cancer Center - Steubenville, Steubenville, Ohio, United States
- UPMC Cancer Center - Beaver, Beaver, Pennsylvania, United States
- UPMC Cancer Center - Clairton, Clairton, Pennsylvania, United States
- UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg, Greensburg, Pennsylvania, United States
- UPMC Cancer Center - Oakbrook Commons - Greensburg, Greensburg, Pennsylvania, United States
- UPMC Cancer Center - Indiana, Indiana, Pennsylvania, United States
- UPMC Cancer Center - John P. Murtha Pavilion - Johnstown, Johnstown, Pennsylvania, United States
- UPMC Cancer Center - McKeesport, McKeesport, Pennsylvania, United States
- UPMC Cancer Center -Haymaker Rd., Monroeville, Pennsylvania, United States
- UPMC Cancer Center -Mosside Blvd., Monroeville, Pennsylvania, United States
- UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group, Moon Township, Pennsylvania, United States
- UPMC Cancer Center -Mt. Pleasant, Mount Pleasant, Pennsylvania, United States
- UPMC Cancer Center -New Castle, New Castle, Pennsylvania, United States
- UPMC Cancer Center -Delafield Rd., Pittsburgh, Pennsylvania, United States
- UPMC Cancer Center - Mercy, Pittsburgh, Pennsylvania, United States
- +6 more locations on ClinicalTrials.gov
Collaborators
Millennium Pharmaceuticals, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00581360 on ClinicalTrials.govOther trials for Adenoid cystic carcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07507578A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic CarcinomaFondazione IRCCS Istituto Nazionale dei Tumori, Milano
- RECRUITINGPHASE2NCT06781567Clinical Trial of HG146 Administered to Participants with Adenoid Cystic CarcinomaHitGen Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT04209660Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT04214366Adenoid Cystic Carcinoma and Carbon Ion Only IrradiationHeidelberg University
- RECRUITINGPHASE1, PHASE2NCT03556228VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaVM Oncology, LLC
See all trials for Adenoid cystic carcinoma of the cervix uteri →